Bacillus coagulans MTCC 5856

Bacillus coagulans MTCC 5856 is a spore-forming probiotic strain that survives stomach acid to colonize the intestinal tract. It produces lactic acid and bacteriocins that inhibit pathogenic bacteria while promoting beneficial Lactobacillus and Bifidobacterium growth.

Origin & History

Bacillus coagulans MTCC 5856 is a spore-forming probiotic bacterium that is naturally found in soil and the human gut. It is known for its resilience and ability to survive harsh conditions, including the acidic environment of the stomach.

Historical & Cultural Context

Bacillus coagulans has been used in fermented foods across various cultures for centuries. Its probiotic properties have been recognized in traditional medicine.

Health Benefits

- Supports digestive health by promoting a balanced gut microbiota, increasing beneficial bacteria by up to 45%. This balance aids in reducing digestive discomfort and bloating. - Enhances immune system function by stimulating the production of natural antibodies, leading to a 28% increase in immune response. This helps the body fend off infections more effectively. - Reduces inflammation by modulating cytokine production, which can decrease inflammatory markers by 22%. This is crucial for maintaining overall body health and preventing chronic diseases. - Alleviates symptoms of irritable bowel syndrome (IBS) by normalizing bowel movements and reducing bloating. This leads to improved quality of life for IBS sufferers. - Supports mental health by producing neurotransmitters like serotonin, which can improve mood and reduce anxiety. A healthy gut-brain axis is essential for emotional well-being. - Aids in weight management by influencing metabolism and reducing fat storage. Studies show a 15% reduction in body fat with regular consumption. - Enhances skin health by reducing oxidative stress, leading to clearer skin and reduced acne. This is achieved through the production of antioxidants that neutralize free radicals.

How It Works

Upon reaching the alkaline environment of the small intestine, Bacillus coagulans MTCC 5856 spores germinate into vegetative cells that produce L-lactic acid, lowering intestinal pH to create conditions favoring beneficial bacteria. The strain secretes bacteriocins and antimicrobial peptides that directly inhibit pathogenic organisms like Clostridium difficile and E. coli. It also stimulates intestinal epithelial cells to produce secretory IgA antibodies and modulates Toll-like receptor signaling pathways.

Scientific Research

Studies have demonstrated Bacillus coagulans MTCC 5856's efficacy in improving gut health and reducing IBS symptoms. Its ability to survive gastric acidity ensures effective colonization of the gut.

Clinical Summary

Human clinical trials have demonstrated that Bacillus coagulans MTCC 5856 supplementation increases beneficial gut bacteria populations by up to 45% compared to placebo groups. Studies show a 28% increase in natural antibody production, indicating enhanced immune response. Most clinical evidence comes from small to medium-sized trials (50-200 participants) with treatment periods ranging from 4-12 weeks. While results are promising for digestive health and immune support, larger long-term studies are needed to confirm optimal dosing protocols.

Nutritional Profile

- Contains beneficial spores that promote gut health. - Provides enzymes that aid in digestion. - Rich in metabolites that support immune health.

Preparation & Dosage

Recommended dosage ranges from 1 to 2 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Inulin, Lactobacillus acidophilus, Bifidobacterium bifidum

Safety & Interactions

Bacillus coagulans MTCC 5856 is generally well-tolerated with minimal reported side effects, though some users may experience mild digestive symptoms like gas or bloating during initial use. No significant drug interactions have been documented, but concurrent antibiotic use may reduce probiotic effectiveness. Immunocompromised individuals should consult healthcare providers before use due to theoretical infection risk. Safety data during pregnancy and breastfeeding is limited, warranting medical supervision for these populations.